Arizona State Retirement System Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

The Arizona State Retirement System reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 5.7% in Q4 2025, now holding 29,232 shares valued at $22.56 million. This partial divestment comes as Regeneron experiences a mix of positive news, such as FDA approval for its gene therapy Otarmeni and strong Q4 earnings, alongside potential pressures like a drug-pricing “most-favored-nation” deal. Analysts currently rate REGN as a “Moderate Buy” with a consensus target price of $825.35.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin